Csenge Advisory Group’s Anika Therapeutics ANIK Stock Holding History

Csenge Advisory Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4	Closed	–	–	263
2018 Q3	$0	Buy	+4	New	+$158	﹤0.01%	1032

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Csenge Advisory Group's ANIK Position: Q4 2018 in Review

Csenge Advisory Group sold out of Anika Therapeutics (ANIK) in Q4 2018, closing a stake of 4 shares.

Csenge Advisory Group first reported a position in ANIK in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 162 funds tracked by Wall St. Rank hold ANIK as of Q4 2018.

Csenge Advisory Group reported no remaining Anika Therapeutics position as of Q4 2018 after selling out during the quarter.
Csenge Advisory Group sold 4 Anika Therapeutics shares in Q4 2018.
Csenge Advisory Group first reported a position in Anika Therapeutics in Q3 2018 and held it in 1 quarter.
Csenge Advisory Group's Anika Therapeutics position peaked at $0 in Q3 2018.
162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.